Comera Life Sciences Holdings, Inc. (CMRA)
| Market Cap | 1.69M |
| Revenue (ttm) | 1.00M |
| Net Income (ttm) | -84.25M |
| Shares Out | 30.74M |
| EPS (ttm) | -4.54 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 26,194 |
| Open | 0.0550 |
| Previous Close | 0.0550 |
| Day's Range | 0.0550 - 0.0750 |
| 52-Week Range | 0.0300 - 2.1700 |
| Beta | 0.45 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 9, 2023 |
About CMRA
Comera Life Sciences Holdings, Inc., a preclinical stage life sciences company, develops an internal portfolio of proprietary therapeutics that incorporate its proprietary formulation platform. Its SQore platform is designed to enable the conversion of intravenous biologics to subcutaneous versions. The company's lead pipeline candidate is CLS-001, a subcutaneous formulation of vedolizumab for the treatment of inflammatory bowel disease, including Crohn's disease and ulcerative colitis. Comera Life Sciences Holdings, Inc. was founded in 2014 an... [Read more]
Financial Performance
In 2022, CMRA's revenue was $633,102, an increase of 97.95% compared to the previous year's $319,832. Losses were -$24.04 million, 354.3% more than in 2021.
Financial StatementsNews
Comera Life Sciences Announces Process Exploring Strategic Alternatives
WOBURN, Mass., Dec. 06, 2023 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (OTCQB: CMRA) (“Comera” or the “Company”), a life sciences company developing a new generation of biologic medicine...
Comera Life Sciences Appoints Dorothy Clarke to Board of Directors
WOBURN, Mass., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA), a life sciences company developing a new generation of biologic medicines to improve patient access...
Comera Life Sciences Reports Financial Results for Third Quarter 2023 and Recent Business Highlights
– Final stage of technical evaluation near completion in Comera's research collaboration with Regeneron, a leading U.S. biotechnology company –
Comera Life Sciences Presents SQore™ Platform Technology Data at PODD: Partnerships in Drug Delivery Conference
WOBURN, Mass., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA), a life sciences company developing a new generation of biologic medicines to improve patient access...
Comera Life Sciences Announces Publication of Study Reinforcing Caffeine's Viscosity Reducing Capabilities
Data published in the Journal of Pharmaceutical Sciences support further development of caffeine as a viscosity reducing agent for subcutaneous formulations of monoclonal antibodies
Comera Life Sciences Reports Financial Results for Second Quarter 2023 and Recent Business Highlights
– Advanced to final stage of technical evaluation in Comera's research collaboration with Regeneron, a leading U.S. biotechnology company –
Comera Life Sciences Significantly Expands Intellectual Property Portfolio Strengthening the Proprietary SQore™ Platform
WOBURN, Mass., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA), a life sciences company developing a new generation of biologic medicines to improve patient access...
Comera Life Sciences Announces Collaboration with Quality Chemical Laboratories to Secure Proprietary Supply of SQore Excipients
– Ownership of proprietary sourcing for U.S.-manufactured lead SQore excipients allows for full control over supply chain and greater flexibility to support product development needs –
Comera Life Sciences Reports Financial Results for First Quarter 2023 and Recent Business Highlights
– Significant progress in Comera's ongoing research collaboration with Regeneron, a leading U.S. biotechnology company –
Comera Life Sciences to Participate in Four Upcoming Conferences
WOBURN, Mass., April 27, 2023 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA) (“Company” or “Comera”), a life sciences company developing a new generation of bio-innovative biol...
Comera Life Sciences Announces Expansion of Patent Portfolio Underlying Core Excipient Technology
Notice of Allowance of U.S. patent application received for expansion of core viscosity reduction claims for excipients in SQore™ platform.
Comera Life Sciences Reports Financial Results for Fourth Quarter and Full Year 2022 and Recent Business Highlights
– Extended and broadened its ongoing research collaboration with Regeneron, a leading U.S. biotechnology company –
Comera Life Sciences to Present at 22nd Annual PepTalk Conference
WOBURN, Mass., Jan. 12, 2023 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA) (“Company” or “Comera”), a life sciences company developing a new generation of bio-innovative biolo...
Comera Life Sciences Closes $3.6 Million Private Placement Priced At-the-Market under Nasdaq Rules
WOBURN, Mass., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA), a life sciences company developing a new generation of bio-innovative biologic medicines to improve...
Comera Life Sciences to Participate in the Benchmark Company's Upcoming Discovery One-on-One Investor Conference
WOBURN, Mass., Nov. 17, 2022 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA), a life sciences company developing a new generation of bio-innovative biologic medicines to improve...
Comera Life Sciences Reports Financial Results for Third Quarter 2022 and Business Highlights
– Extended and broadened its ongoing research collaboration with Regeneron, a leading U.S. biotechnology company –
Comera Life Sciences Announces Favorable Preclinical Results of Lead SQore Excipient in SEQURUS-2 Study
WOBURN, Mass., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA), a life sciences company developing a new generation of bio-innovative biologic medicines to improve...
Comera Life Sciences Expands Woburn Operations
Elected Officials, Industry Leaders Celebrate Biotech Workforce Growth at Ribbon-Cutting Event
Comera Life Sciences Announces Up To $15 million Purchase Agreement with Arena Business Solutions
WOBURN, Mass., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA) (“Company” or “Comera”), a life sciences company developing a new generation of bio-innovative biolo...
Comera Life Sciences Provides Business Highlights and Reports Financial Results for the Second Quarter 2022
WOBURN, Mass., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA), a life sciences company developing a new generation of bio-innovative biologic medicines to improve...
Comera Life Sciences Announces Issuance of U.S. Patent for Proprietary Excipients in SQore Platform
WOBURN, Mass.--(BUSINESS WIRE)--Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA), a life sciences company developing a new generation of bio-innovative biologic medicines to improve patient access, ...
Comera Life Sciences Appoints Michael Campbell as Executive Vice President and Chief Financial Officer
WOBURN, Mass.--(BUSINESS WIRE)--Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA), a life sciences company developing a new generation of bio-innovative biologic medicines to improve patient access, ...
What's Going On With OTR Acquisition Stock Today?
OTR Acquisition Corp (NASDAQ: OTRA) shares are trading higher Wednesday after the company filed a Form 8-K with the U.S. Securities and Exchange Commision. The move appears to be related to the high n...
Comera Life Sciences Announces Research Collaboration with Top 10 Pharmaceutical Company to Develop Subcutaneous Formulation
WOBURN, Mass.--(BUSINESS WIRE)--Comera Life Sciences, Inc. (“Comera” or the “Company”), which is developing a new generation of bio-innovative biologic medicines to improve patient access, safety, and...
Comera Life Sciences to Present at 18th Annual PEGS Boston Conference & Expo
WOBURN, Mass.--(BUSINESS WIRE)--Comera Life Sciences, Inc., which is developing a new generation of bio-innovative biologic medicines to improve patient access, safety, and convenience, today announce...